Darrell Borger Email & Phone Number

Cambridge, MA, US

Cambridge, Massachusetts, United States

Founded and directed Takeda's Experimental & Molecular Pathology Unit, integrating translational expertise, on-site laboratory capabilities, advanced tissue-based technologies, and informatics to uncover breakthrough drug targets, complex mechanisms of action, and predictive biomarkers of therapeutic response. Notable achievements include pioneering.

Cambridge, United States

Recruited key academic and biotechnology subject matter experts, developed a highly integrated investigative immunohistology team, improved image informatics capabilities, and overhauled preclinical laboratory practices to enhance workflow efficiency and maximize data quality. By integrating translational scientists directly into oncology drug discovery.

Greater Boston Area

Created and managed a preclinical lab group within the Biomarker Unit to advance precision medicine in immunotherapy. Pioneered multiplexed expression profiling and multispectral imaging to uncover immune escape mechanisms in various solid tumors. Secured a research partnership with Tesaro to identify immune checkpoint signatures in endometrial and.

Transformed a unit to implement a precision medicine approach, stratifying patients for early-phase clinical trials of small molecule inhibitors based on tumor fingerprints. Managed a central testing laboratory for six oncology trials with leading pharmaceutical companies, developing and validating genotyping assays for patient eligibility determination.

Served as an integral member of a small pathology team that developed a new generation of multiplexed clinical genotyping platforms to identify oncogenic gene mutations that could rationally inform small molecule therapy choice for patients. Developed a clinical testing lab under CLIA & New York State certification that provided one of the first examples.

Greater Boston Area

• Identified novel molecular signatures in various rare malignancies, leading to the development of new phase I and II clinical trials in collaboration with MGH oncologists and leading pharmaceutical companies.
• Co-identified an EGFR gene amplification signature in vulvar cancer (PMID: 18768215), prompting an MGH-sponsored phase II clinical trial of erlotinib treatment in this historically underserved patient population (PMID.
• First to report mutations in isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma (PMID: 22180306), leading to an MGH clinical trial evaluating ivosidenib (PMID: 32416072) and subsequent FDA orphan drug.

Discovered specific cancer survival mechanisms under low oxygen conditions and the co-opting of coactivators by a viral oncoprotein, supported through NIH funding.